KDM6A deficiency promotes tumor progression and resistance to cabozantinib treatment in clear cell renal cell carcinoma
8.5
来源：
Nature
关键字：
mRNA
发布时间：
2025-11-05 07:50
摘要：
KDM6A deficiency is linked to tumor progression and resistance to tyrosine kinase inhibitors (TKIs) in clear cell renal cell carcinoma (ccRCC). The study reveals that low KDM6A expression correlates with poor patient prognosis and enhances cancer stemness and epithelial-mesenchymal transition (EMT) properties. Furthermore, KDM6A-deficient cells exhibit reduced sensitivity to cabozantinib, suggesting that targeting KDM6A-related pathways could provide new therapeutic strategies for ccRCC patients.
原文：
查看原文
价值分投票
评分标准
新闻价值分采用0-10分制，综合考虑新闻的真实性、重要性、时效性、影响力等多个维度。
评分越高，表示该新闻的价值越大，越值得关注。
价值维度分析
domain_focus
1.0分+1.0分
business_impact
0.8分+0.8分
scientific_rigor
1.5分+1.5分
timeliness_innovation
1.5分+1.5分
investment_perspective
2.5分+2.5分
market_value_relevance
1.0分+1.0分
team_institution_background
0.5分+0.5分
technical_barrier_competition
1.0分+1.0分
关键证据
KDM6A deficiency correlates with poor prognosis in ccRCC patients.
KDM6A-deficient cells show resistance to cabozantinib.
KDM6A deficiency enhances invasion, migration, and cancer stemness.
真实性检查
否
AI评分总结
KDM6A deficiency is linked to tumor progression and resistance to tyrosine kinase inhibitors (TKIs) in clear cell renal cell carcinoma (ccRCC). The study reveals that low KDM6A expression correlates with poor patient prognosis and enhances cancer stemness and epithelial-mesenchymal transition (EMT) properties. Furthermore, KDM6A-deficient cells exhibit reduced sensitivity to cabozantinib, suggesting that targeting KDM6A-related pathways could provide new therapeutic strategies for ccRCC patients.